Varenicline Solution Nasal Spray: A Review in Dry Eye Disease

Abstract

Increasing endogenous tear film production via pharmacological neuroactivation of the nasolacrimal reflex [NLR; also known as the trigeminal parasympathetic pathway (TPP)] is a novel therapeutic approach to treating dry eye disease (DED). An intranasal formulation of the water-soluble, small-molecule, nicotinic acetylcholine receptor (nAChR) agonist varenicline (Tyrvaya™) has been approved in the USA for the treatment of DED. Twice-daily administration of varenicline solution nasal spray resulted in rapid, statistically significant and clinically meaningful improvements in the signs and symptoms of DED over a period of 4 weeks in two pivotal studies (ONSET-1 and -2). The efficacy of varenicline solution was maintained over a longer-term period of 12 weeks in a third study (MYSTIC). Consistent with the nasal route of delivery, the most common adverse events reported by varenicline solution recipients were non-ocular in nature (mild and transient sneezing and cough). Thus, varenicline solution nasal spray is a rapidly-acting, effective and generally well tolerated treatment for DED that offers several potentially useful advantages over existing topical ocular therapies in terms of increasing endogenous tear secretion and reducing ophthalmic treatment burden. Supplementary Information The online version contains supplementary material available at 10.1007/s40265-022-01782-4.

The Efficacy and Safety of Rebamipide Ophthalmic Suspension (OPC-12759) in Patients with Dry Eye Disease: A Systematic Review of Randomized Controlled Trials

“…Topical cyclosporine and lifitegrast studies have reported that burning is the main ocular AEs with an overall compliance of 80.2% [45,55,59] and 91.1 [60][61][62], respectively. Varenicline nasal spray, which has recently been approved for DED treatment [63], seems to reduce the common AEs of topical ocular application modalities by achieving an overall compliance of 95.4% [64][65][66]. However, this systematic review has reported an overall compliance with REB ophthalmic suspension treatment of 96.8 ± 3.4%.…”

The Evolving Landscape of Dry Eye Disease Therapies

“…Overall, most of the adverse events are tolerable and lifitegrast can alleviate refractory DED and improves patients' quality of life [11]. The recently introduced varenicline, a nicotinic acetylcholine receptor agonist, is innovative in its route of administration [12]. Given as a nasal spray, varenicline acts rapidly and is effective and generally well tolerated, with its increase in endogenous tear secretion being a potentially useful advantage over existing therapies.…”

Management of Sjogren’s Dry Eye Disease—Advances in Ocular Drug Delivery Offering a New Hope

“…It is a nicotinic acetylcholine receptor agonist that binds to the nasociliary nerve within the nasal cavity. Four weeks of treatment saw improved results at week 12 [ 36 , 37 ]. Pharmacy-sponsored studies show significant improvement after 4 weeks of treatment and showed significantly better results compared to lifitegrast.…”